Komipharm International Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 12, 2022 at 10:34 am IST
Share
Komipharm International Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 431.09 million compared to KRW 299.63 million a year ago. Net income was KRW 1,106.31 million compared to net loss of KRW 870.27 million a year ago. Basic earnings per share from continuing operations was KRW 17 compared to basic loss per share from continuing operations of KRW 14 a year ago. Diluted earnings per share from continuing operations was KRW 17 compared to diluted loss per share from continuing operations of KRW 14 a year ago. Basic earnings per share was KRW 17 compared to basic loss per share of KRW 14 a year ago.
For the six months, sales was KRW 989.94 million compared to KRW 531.74 million a year ago. Net income was KRW 1,008.46 million compared to KRW 88.7 million a year ago. Basic earnings per share from continuing operations was KRW 16 compared to KRW 1 a year ago. Diluted earnings per share from continuing operations was KRW 16 compared to KRW 1 a year ago. Basic earnings per share was KRW 16 compared to KRW 1 a year ago.
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
KOMIPHARM INTERNATIONAL CO., LTD. 
